VenatoRx Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-06-04
- Employees
- 51
- Market Cap
- -
- Website
- http://www.venatorx.com
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
Phase 1
Active, not recruiting
- Conditions
- Healthy VolunteerPharmacokineticsSafetyDrug-Drug Interaction (DDI)FDC
- Interventions
- Drug: Ceftibuten-ledaborbactam etzadroxil
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT06733675
- Locations
- 🇺🇸
ICON, Clinical Research Phase I Unit, Lenexa, Kansas, United States
Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age
Phase 1
Completed
- Conditions
- PharmacokineticsHealthy Volunteers
- Interventions
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT06665555
- Locations
- 🇺🇸
Pulmonary Associates, Phoenix, Arizona, United States
Cefepime-taniborbactam Vs Meropenem in Adults with VABP or Ventilated HABP
Phase 3
Withdrawn
- Conditions
- Ventilator-associated PneumoniaHospital-acquired Pneumonia
- Interventions
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 316
- Registration Number
- NCT06168734
Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05527834
- Locations
- 🇺🇸
ICON Plc., Lenexa, Kansas, United States
Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05488678
- Locations
- 🇺🇸
Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Advanced Pharma, Miami, Florida, United States
Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Subjects
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04951505
- Locations
- 🇺🇸
Pulmonary Associates PA, Phoenix, Arizona, United States
VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT04877379
- Locations
- 🇳🇱
PRA Health Sciences - Early Development Services, Groningen, Netherlands
VNRX-9945 Safety and Pharmacokinetics in Healthy Adult Volunteers
Phase 1
Terminated
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo for VNRX-9945
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04845321
- Locations
- 🇳🇿
New Zealand Clinical Research, Auckland, New Zealand
VNRX-5024 Safety and PK in Healthy Adult Volunteers
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04314206
- Locations
- 🇳🇱
PRA Health Sciences - Early Development Services, Groningen, Netherlands
VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT04243863
- Locations
- 🇺🇸
Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath